This study is completed in the United States, in Canada, in the United Kingdom, .... It is testing sirukumab for depression.
DepressionDrugFrom 21 Years to 64 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether Sirukumab may be useful for adults experiencing depression.
What would participation involve?
Participants may receive Sirukumab, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Canada, in Poland, and in Russia.
Who is it mainly for?
This study appears to be mainly for adults with depression.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: July 23, 2015
Recruitment status
Completed
Enrollment listed in the registry
193
Sponsor
Janssen Research & Development, LLC
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Canada, United Kingdom, ...
Age range
From 21 Years to 64 Years
Official registry ID
NCT02473289
Official title
A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a Monoaminergic Antidepressant in Adults With Major Depressive Disorder
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT02473289. We help you review the study, but cannot decide medical eligibility.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Canada · 4 sites
Edmonton
Edmonton, Alberta
Site status: Not listed — confirm with the team
Chatham
Chatham, Ontario
Site status: Not listed — confirm with the team
Hamilton
Hamilton, Ontario
Site status: Not listed — confirm with the team
Toronto
Toronto, Ontario
Site status: Not listed — confirm with the team
Poland · 5 sites
Bełchatów
Bełchatów
Site status: Not listed — confirm with the team
Bydgoszcz
Bydgoszcz
Site status: Not listed — confirm with the team
Chełmno
Chełmno
Site status: Not listed — confirm with the team
Gorlice
Gorlice
Site status: Not listed — confirm with the team
Lublin
Lublin
Site status: Not listed — confirm with the team
Russia · 9 sites
Karelia
Karelia
Site status: Not listed — confirm with the team
Moscow
Moscow
Site status: Not listed — confirm with the team
Nizny Novgorod
Nizny Novgorod
Site status: Not listed — confirm with the team
Rostov-on-Don
Rostov-on-Don
Site status: Not listed — confirm with the team
Saint Petersburg
Saint Petersburg
Site status: Not listed — confirm with the team
Saratov
Saratov
Site status: Not listed — confirm with the team
Saratov Region
Saratov Region
Site status: Not listed — confirm with the team
Tomsk
Tomsk
Site status: Not listed — confirm with the team
Yaroslavl
Yaroslavl
Site status: Not listed — confirm with the team
United Kingdom · 4 sites
Edinburgh
Edinburgh
Site status: Not listed — confirm with the team
Glasgow
Glasgow
Site status: Not listed — confirm with the team
Oxford
Oxford
Site status: Not listed — confirm with the team
Redruth
Redruth
Site status: Not listed — confirm with the team
United States · 24 sites
Birmingham
Birmingham, Alabama
Site status: Not listed — confirm with the team
Little Rock
Little Rock, Arkansas
Site status: Not listed — confirm with the team
Bellflower
Bellflower, California
Site status: Not listed — confirm with the team
Glendale
Glendale, California
Site status: Not listed — confirm with the team
Lemon Grove
Lemon Grove, California
Site status: Not listed — confirm with the team
Orange
Orange, California
Site status: Not listed — confirm with the team
Santa Ana
Santa Ana, California
Site status: Not listed — confirm with the team
Torrance
Torrance, California
Site status: Not listed — confirm with the team
Wildomar
Wildomar, California
Site status: Not listed — confirm with the team
Atlanta
Atlanta, Georgia
Site status: Not listed — confirm with the team
Decatur
Decatur, Georgia
Site status: Not listed — confirm with the team
Chicago
Chicago, Illinois
Site status: Not listed — confirm with the team
Edgewood
Edgewood, Kentucky
Site status: Not listed — confirm with the team
Baltimore
Baltimore, Maryland
Site status: Not listed — confirm with the team
Grand Rapids
Grand Rapids, Michigan
Site status: Not listed — confirm with the team
Lebanon
Lebanon, New Hampshire
Site status: Not listed — confirm with the team
Brooklyn
Brooklyn, New York
Site status: Not listed — confirm with the team
New York
New York, New York
Site status: Not listed — confirm with the team
Staten Island
Staten Island, New York
Site status: Not listed — confirm with the team
Columbus
Columbus, Ohio
Site status: Not listed — confirm with the team
Oklahoma City
Oklahoma City, Oklahoma
Site status: Not listed — confirm with the team
Houston
Houston, Texas
Site status: Not listed — confirm with the team
Plano
Plano, Texas
Site status: Not listed — confirm with the team
Salt Lake City
Salt Lake City, Utah
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Sirukumab 50 mg, Placebo. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.
Who might this study be for?
This study may concern people with depression; age range: From 21 Years to 64 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Janssen Research & Development, LLC, which appears to be another type of organization. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
